Blazing Biotechs Highlights Stocks Trading Under $ 10 With Massive Upside Potential – 24/7 Wall St.
While most of Wall Street focuses on large and large cap stocks because they provide a degree of safety and liquidity, many investors are limited in the number of stocks they can buy. Many of the largest public companies, especially the tech giants, trade in the hundreds, up to over $ 1,000 a share or more. At these high prices, it’s hard to get decent leverage on the number of shares.
Many investors, especially the more aggressive traders, see low-priced stocks as a way to not only make money, but also get more stocks. It can really help the decision making process especially when you are on a winner because you can always sell half and keep half.
We sifted through our 24/7 Wall St. research database for smaller cap companies that could very well offer patient investors huge returns for the remainder of 2021 and beyond. Many of the world’s largest companies, including Apple and Amazon, have traded in single digits at some point.
Although the following four actions are rated Buy, it is important to remember that no analyst report should be used as the sole basis for any decision to buy or sell.
This company might be well under the radar, but it has one of the best products imaginable when it comes to brand awareness. Arcos Dorados Holdings Inc. (NYSE: ARCO) is the world’s largest independent McDonald’s franchisee.
The company has the exclusive right to own, operate and license McDonald’s restaurants in 20 countries and territories in Latin America and the Caribbean. As of December 31, 2020, it operated or franchised 2,236 restaurants.
JPMorgan has a price target of $ 8.50 and the Wall Street consensus target is $ 6.55. The shares closed Friday at $ 5.95.
This clinical-stage biotech company recently received some big patent news. Axcella Health Inc. (NASDAQ: AXLA) researches and develops endogenous metabolic modulators for the treatment of complex diseases and the improvement of health in the United States.
The company offers AXA1665 for the treatment of overt hepatic encephalopathy, and AXA1125 and AXA1957 for the treatment of non-alcoholic steatohepatitis. It is also developing AXA4010, a product candidate in hematology, and AXA2678, a product candidate for muscle.
The company recently announced that it has activated initial clinical sites and patient screening for its global Phase 2 clinical trial of AXA1665, the company’s multi-target oral product candidate for reducing the risk of hepatic encephalopathy. recurrent manifesto.
HC Wainwright recently started hedging with a massive $ 14 price target, but that pales in comparison to the even bigger consensus target of $ 15.13. Friday’s final trade came in at $ 4.06, up more than 4%.
Despite low brand awareness, this could be a home run for aggressive investors. Jaguar Health Inc. (NASDAQ: JAGX), a commercial-stage pharmaceutical company, focuses on the development of prescription drugs for people and animals with gastrointestinal disorders, particularly chronic and debilitating diarrhea.
Through its subsidiary Napo Pharmaceuticals, the company is focused on the development and commercialization of proprietary herbal human gastrointestinal pharmaceuticals from plants responsibly harvested from rainforest areas. It markets Mytesi, a 125 mg delayed-release tablet of crofelemer for the symptomatic relief of non-infectious diarrhea in adults with HIV / AIDS on antiretroviral therapy.